Exploring risk in the medical cannabis supply chain

Glass Pharms contributed to this insightful view of supply chain risk in medical cannabis as it matures to a substantial industry.

This Relm Risk Briefing: Cannabis 2026 shares learnings from that experience. It investigates how regulation, insurance, and operational practice intersect across the global supply chain, drawing on data and conversations with market leaders who are setting new standards in safety, sustainability, and accountability.

Read More